concept

WHITE MATTER

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about WHITE MATTER: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

544Connections

7Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

WHITE MATTER is a concept in neurodegeneration research. Key relationships include: co discussed, activates, causes. Associated with ALS, ANXIETY, DEMENTIA. Connected to 36 entities in the SciDEX knowledge graph.

View on Wiki →

💡 Concept Info

Name	WHITE MATTER
Key Genes/Proteins	APOE
Related Diseases	ALS, PROTEIN AGGREGATION, LIPID PEROXIDATION, NEURODEGENERATION, AGING
Linked Hypotheses	7 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

cbs-psp-daily-action-plan

therapeutic · 30834 words

→

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

→

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

therapeutic · 15567 words

→

Progressive Supranuclear Palsy (PSP)

disease · 12907 words

→

Corticobasal Syndrome (CBS)

disease · 11374 words

→

Pathway Diagram

graph TD
    WHITE_MATTER["WHITE MATTER"]
    AQUAPORIN_4["AQUAPORIN-4"] -->|"expressed in"| WHITE_MATTER
    MYELIN["MYELIN"] -->|"expressed in"| WHITE_MATTER
    OLIGODENDROCYTE["OLIGODENDROCYTE"] -->|"expressed in"| WHITE_MATTER
    AQP4["AQP4"] -->|"expressed in"| WHITE_MATTER
    MITOCHONDRIAL_DYSFUNCTION["MITOCHONDRIAL DYSFUNCTION"] -->|"expressed in"| WHITE_MATTER
    JAM2["JAM2"] -->|"expressed in"| WHITE_MATTER
    JUN["JUN"] -->|"expressed in"| WHITE_MATTER
    GENES["GENES"] -->|"expressed in"| WHITE_MATTER
    XPR1["XPR1"] -->|"expressed in"| WHITE_MATTER
    SLC20A2["SLC20A2"] -->|"expressed in"| WHITE_MATTER

Outgoing (117)

Target	Relation	Type	Str
ALS	treats	disease	0.70
APOE	treats	gene	0.70
APOE	stabilizes	gene	0.70
APOE	regulates	gene	0.70
PROTEIN AGGREGATION	stabilizes	phenotype	0.70
PROTEIN AGGREGATION	activates	phenotype	0.70
NEURON	stabilizes	cell_type	0.70
LIPID PEROXIDATION	causes	phenotype	0.70
NEURODEGENERATION	increases_risk	phenotype	0.70
TRAUMATIC BRAIN INJURY	causes	disease	0.65
MICROGLIA	produces	cell_type	0.65
NEUROINFLAMMATION	regulates	phenotype	0.65
PSEN1	interacts_with	gene	0.65
NECROPTOSIS	regulates	phenotype	0.65
ALZHEIMER'S DISEASE	regulates	disease	0.65
ALZHEIMER'S DISEASE	interacts_with	disease	0.65
TREM2	regulates	gene	0.65
ALZHEIMER'S DISEASE	implicated_in	disease	0.60
TAU	targets	protein	0.60
FORNIX	stabilizes	brain_region	0.60
FORNIX	treats	brain_region	0.60
CORPUS CALLOSUM	treats	brain_region	0.60
APP	associated_with	gene	0.50
PERICYTE	associated_with	cell_type	0.50
CXCL10	associated_with	gene	0.50
T CELLS	associated_with	cell_type	0.50
L-DOPA	associated_with	drug	0.50
MOG	associated_with	gene	0.50
AMPK	associated_with	gene	0.50
GFAP	associated_with	gene	0.50
HUNTINGTON	associated_with	disease	0.50
APOPTOSIS	associated_with	phenotype	0.50
CYTOKINES	associated_with	phenotype	0.50
BDNF	associated_with	gene	0.50
GDNF	associated_with	gene	0.50
ROS	associated_with	phenotype	0.50
NLRP3	associated_with	gene	0.50
STING	associated_with	gene	0.50
CHOLESTEROL	associated_with	phenotype	0.50
CYP46A1	associated_with	gene	0.50
HDAC3	associated_with	gene	0.50
SENESCENCE	associated_with	phenotype	0.50
MTOR	associated_with	gene	0.50
PI3K	associated_with	gene	0.50
AKT	associated_with	gene	0.50
TNF	associated_with	gene	0.50
SYK	associated_with	gene	0.50
OLIG2	associated_with	gene	0.50
MBP	associated_with	gene	0.50
B CELLS	associated_with	cell_type	0.50

Incoming (427)

Source	Relation	Type	Str
ALS	stabilizes	disease	0.70
AGING	stabilizes	phenotype	0.70
GRAY MATTER	stabilizes	brain_region	0.70
GRAY MATTER	treats	brain_region	0.70
AGING	treats	phenotype	0.70
MICROGLIAL ACTIVATION	treats	phenotype	0.70
CYP46A1	activates	gene	0.70
CORTEX	reduces	brain_region	0.65
ENTORHINAL	reduces	brain_region	0.65
NRF2	activates	gene	0.65
STING	activates	gene	0.65
MICROGLIA	promotes	cell_type	0.65
NRF2	promotes	gene	0.65
ISCHEMIC	causes	disease	0.65
NEURON	expressed_in	cell_type	0.65
OLIGODENDROCYTES	activates	cell_type	0.65
CORTEX	phosphorylates	brain_region	0.65
TAU	phosphorylates	gene	0.65
NEURON	impairs	cell_type	0.65
TRAUMATIC BRAIN INJURY	contributes_to	disease	0.65
NRF2	regulates	gene	0.65
OLIGODENDROCYTE	regulates	cell_type	0.65
GLUTAMATE	produces	phenotype	0.65
AGING	exacerbates	phenotype	0.65
MACROPHAGES	causes	cell_type	0.65
GLUTAMATE	transports	phenotype	0.65
PHAGOCYTOSIS	inhibits	phenotype	0.65
OLIGODENDROCYTES	causes	cell_type	0.65
CURCUMIN	treats	drug	0.65
STROKE	protects_against	disease	0.65
MICROGLIA	protects_against	cell_type	0.65
BASAL GANGLIA	activates	brain_region	0.65
OLIGODENDROCYTE	causes	cell_type	0.65
CHOLESTEROL	causes	phenotype	0.65
CHOLESTEROL	activates	phenotype	0.65
SMPD1	inhibits	gene	0.65
GLUTAMATE	targets	phenotype	0.65
VEGFA	interacts_with	gene	0.65
CORTEX	expressed_in	brain_region	0.60
HIPPOCAMPUS	expressed_in	brain_region	0.60
TREM2	causes	gene	0.60
MICROGLIA	causes	cell_type	0.60
MICROGLIA	associated_with	cell_type	0.60
DEMENTIA	causes	disease	0.60
ISCHEMIC	treats	disease	0.60
MICROGLIA	activates	cell_type	0.60
ALS	activates	disease	0.60
MOTOR NEURON	activates	cell_type	0.60
NEURON	activates	cell_type	0.60
NEURON	associated_with	cell_type	0.60

Targeting Hypotheses (7)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drive	0.512	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
OPC differentiation blockade contributes to white matter deg	0.495	Alzheimer's disease	SEA-AD Single-Cell Analysis: Cell-Type V
ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo	0.493	Alzheimer's Disease	Cell type vulnerability in Alzheimers Di
White Matter Oligodendrocyte Protection via CXCL10 Inhibitio	0.480	neurodegeneration	Gene expression changes in aging mouse b
White Matter Vulnerability Prevention via Oligodendrocyte Pr	0.468	neurodegeneration	Gene expression changes in aging mouse b

White Matter Immune Checkpoint Restoration	0.418	neurodegeneration	Gene expression changes in aging mouse b
Oligodendrocyte White Matter Vulnerability	0.398	neurodegeneration	Gene expression changes in aging mouse b

Mentioning Analyses (2)

Scientific analyses that reference this entity

What specific gene expression signatures in aging mouse white matter predict hum

neurodegeneration | 2026-04-11 | 0 hypotheses

Human connectome alterations and network-level dysfunction in Alzheimer disease

neurodegeneration | 2026-04-04 | 0 hypotheses

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyel [PMID:40988129]	Furlan R, Schaedelin S, Frederiksen JL,	Brain	2026
Overlapping autoimmunity and demyelination syndromes associated with TNF inhibit [PMID:41652144]	Daood R, Naffaa ME, Azrilin O, Hassan F,	Clin Rheumatol	2026
Pathogenic mechanisms of action of autoantibody-mediated central nervous system [PMID:41831629]	Lerch M, Irani SR, Ramanathan S	Autoimmun Rev	2026
TRUE-MOGAD Score: A Novel Scoring System to Identify MOGAD Among Positive MOG-Ig [PMID:41921125]	Vilaseca A, Filippatou AG, Said Y, Sechi	Neurol Neuroimmunol Neuroinfla	2026
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. [PMID:41925507]	Flanagan EP, Hemingway C	Continuum (Minneap Minn)	2026
Therapeutic updates in NMOSD and MOGAD: From present practice to future promise. [PMID:41927387]	Elosua-Bayés I, Cobo-Calvo A	Rev Neurol (Paris)	2026
MOGAD update: new phenotypes in the expanding clinical spectrum. [PMID:41942681]	Costello F, Burton JM	J Neurol	2026
Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional [PMID:41956817]	Niederschweiberer M, Bakir C, Vorasoot N	J Neurol Neurosurg Psychiatry	2026
Understanding Further the Phenotypic Spectrum of Central Nervous System Inflamma [PMID:41957957]	Gulec B, Everest E, Tutuncu M, Bilge U,	Ann Clin Transl Neurol	2026
O-GlcNAcylation of UGDH regulates its activity and remodels the extracellular ma [PMID:41053177]	Lin B, Zhou J, Geng D, Chai S, Zhang X e	Cell Death Differ	2026
Mitochondrial NAD(+)-mediated mitophagy alleviates type I interferon response to [PMID:41231107]	Lan T, Shang D, Lin L, Wang H, Zou J et	Autophagy	2026
Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion [PMID:41591814]	Zhang X, Xue J, Zhao C, Zeng C, Zhong J	J Clin Invest	2026
Indole-3-propionic acid inhibits astrocyte inflammation and promotes motor funct [PMID:41663028]	Yu D, Kang J, Jiang W, Zhang C, Zhao X e	Neuropharmacology	2026
Cobrotoxin mitigates neuroinflammation and cognitive impairment by suppressing C [PMID:41671614]	Li Z, Tan B, Dong K, Yu X, Zhang SW et a	Biochem Pharmacol	2026
Peripheral macrophages and T-cells accumulate in the degenerating optic tract af [PMID:41740873]	Main BS, Villapol S, Buenaventura RG, Ha	Brain Behav Immun	2026
Melanoma cell inoculation improves cognitive impairment in the 5xFAD mouse model [PMID:41760781]	Bruna-Jara B, More J, Lobos P, Ponce DP,	Scientific reports	2026
Immune checkpoint inhibitor-associated inflammatory arthritis. [PMID:41800958]	Kim ST, Bass AR	Arthritis Rheumatol	2026
Oxoisoaporphine Alkaloid Piano-Stool Arene Ruthenium(II) Derivative: A cGAS-STIN [PMID:41910318]	Yang LM, Lu Y, Levine MS, Wang X, Shi YQ	J Am Chem Soc	2026
Primary Infection with Cystoisospora suis Modulates Systemic Immunity and the Gu [PMID:41942044]	Ye X, Huang YJ, Deng XL, He ZY, Tan JJ e	Int J Parasitol	2026
CD38 overexpression drives glioblastoma progression via L1CAM/ICAM1/JAK-STAT-Dri [PMID:41946147]	Norouzi S, Aulakh S	Transl Oncol	2026

WHITE MATTER

Understanding Entity Pages

Summary

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Microglia CD8+ T Cell Recruitment -- Supplementary WW Content

calcium-dysregulation-comparison

Corticobasal Degeneration (CBD)

nhp-validation-animal-model

Neuroresilience Mechanisms and Evidence

PI-2620 Tau PET in PSP

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Frontotemporal Dementia (FTD) Mechanistic Pathway

neuroinflammation

CBS/PSP Treatment Rankings

Multiple System Atrophy

Alzheimer's Disease

Frontotemporal Dementia (FTD)

Microglial Cells — Cell Type Hierarchy